To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Last viewed
- José_António_Marques
- Obliteration
- Alcohol_Health_Alliance_UK
- Longer-term Phase III data show Novartis drug Tasigna continues to surpass Glivec in slowing disease progression in CML - Tasigna now approved in the US and Switzerland for this indication; regulatory submissions under review in EU, Japan and other countries worldwide